REGENXBIO Q2 2023 Earnings Report $7.37 +0.22 (+3.08%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast REGENXBIO EPS ResultsActual EPS-$1.66Consensus EPS -$1.26Beat/MissMissed by -$0.40One Year Ago EPS-$1.58REGENXBIO Revenue ResultsActual Revenue$19.98 millionExpected Revenue$34.50 millionBeat/MissMissed by -$14.52 millionYoY Revenue Growth-38.80%REGENXBIO Announcement DetailsQuarterQ2 2023Date8/2/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseRGNX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by REGENXBIO Earnings HeadlinesRegenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121January 16 at 9:37 PM | seekingalpha.comRegenXBio: Strategic Partnerships and Promising Pipeline Drive Buy RatingJanuary 16 at 7:32 AM | markets.businessinsider.comLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!January 19, 2025 | StocksToTrade (Ad)Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)January 15, 2025 | benzinga.comBank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)January 15, 2025 | markets.businessinsider.comRegenxbio stock surges on strategic partnership deal with Nippon ShinyakuJanuary 14, 2025 | investing.comSee More REGENXBIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like REGENXBIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on REGENXBIO and other key companies, straight to your email. Email Address About REGENXBIOREGENXBIO (NASDAQ:RGNX), a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.View REGENXBIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)HDFC Bank (1/21/2025)Charles Schwab (1/21/2025)Prologis (1/21/2025)3M (1/21/2025)Capital One Financial (1/21/2025)ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
